StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Kalaris Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

No ev/ebitda figures for Kalaris Therapeutics

Kalaris Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Kalaris Therapeutics figures

See a number that looks wrong?